Every 10-Q that BioCryst Pharmaceuticals Inc (BCRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BCRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCRX filings page.
BioCryst Pharmaceuticals reported Q2 2026 revenues of $218,250 thousand, up from $163,353 thousand a year earlier, driven by ORLADEYO and higher license and other revenues. Q2 net income was $78,395 thousand, or $0.30 per diluted share, and income from operations was $98,465 thousand.
For the first six months of 2026, revenues were $374,663 thousand, but a $697,761 thousand acquired in‑process R&D expense related to the Astria Therapeutics acquisition led to a net loss of $643,417 thousand, or $2.59 per share. Total consideration for Astria was $874,313 thousand, mostly allocated to the navenibart IPR&D asset and funded in part by a $400,000 thousand term loan under a Blackstone credit agreement. At June 30, 2026, cash and cash equivalents were $154,972 thousand and short‑term investments were $197,601 thousand, while royalty financing obligations totaled $426,789 thousand and the secured term loan balance was $395,400 thousand, contributing to stockholders’ deficit of $454,289 thousand. Management states existing financial resources are expected to fund operations for at least 12 months.
BioCryst Pharmaceuticals completed its acquisition of Astria Therapeutics for total consideration of $874.3M, mainly to obtain the navenibart rare-disease program. The company expensed $697.8M of acquired in-process R&D, driving a quarterly net loss of $721.8M despite revenue of $156.4M, including $148.3M from ORLADEYO. To help fund the cash portion of the deal, BioCryst drew a $400M secured term loan from Blackstone, contributing to total royalty financing obligations and debt of roughly $842.7M. Cash, cash equivalents and restricted cash were $173.4M, while accumulated losses widened and stockholders’ deficit increased to $553.8M.
BioCryst Pharmaceuticals (BCRX) reported Q3 2025 results. Revenue was $159.4 million, up from $117.1 million a year ago, driven mainly by product sales of $157.7 million. Net income reached $12.9 million versus a prior-year loss, equal to $0.06 per diluted share. Year-to-date revenue was $468.3 million with net income of $18.0 million.
Operating cash flow for the nine months was $55.4 million. The company ended the quarter with cash and cash equivalents of $84.1 million, short‑term investments of $128.8 million, and long‑term investments of $39.7 million. On the balance sheet, the secured term loan declined to $194.4 million, and royalty financing obligations were $476.8 million in total. Assets and liabilities classified as held for sale were $29.2 million and $26.4 million, respectively.
BioCryst highlighted continued commercialization of ORLADEYO for HAE prevention, with U.S. distribution concentrated through a single specialty pharmacy. Management stated that financial resources as of September 30, 2025 are expected to fund operations for at least the next 12 months. Shares outstanding were 210.5 million as of October 31, 2025.
BioCryst Pharmaceuticals, Inc. (BCRX) — 10-Q for quarter ended June 30, 2025. Key operational and financial metrics from the filing:
- Revenues: $163,353 thousand (Q2 2025) vs $109,332 thousand (Q2 2024); six months $308,887 thousand vs $202,093 thousand.
- Profitability: Net income $5,085 thousand for Q2 2025 vs a net loss in Q2 2024; six months net income $5,117 thousand vs loss $48,053 thousand.
- Liquidity & balance sheet: Cash and cash equivalents $88,033 thousand; short-term investments $172,005 thousand; total assets $457,188 thousand; stockholders' deficit $(421,594) thousand (improved vs Dec 31, 2024).
- Financing & obligations: Secured term loan $242,794 thousand; royalty financing obligations non-current $447,842 thousand; Pharmakon term loan principal repaid $69,508 thousand year-to-date.
- Other material item: On June 27, 2025 the company entered a definitive agreement to sell BioCryst Ireland (European ORLADEYO business) and has classified assets and liabilities held for sale.
Management states available resources at June 30, 2025 are sufficient to fund operations for at least the next 12 months.